Technical Analysis for DAWN - Day One Biopharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 17.69 | 3.45% | 0.59 |
DAWN closed up 3.45 percent on Wednesday, May 1, 2024, on 1.28 times normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% |
| Alert | Time |
|---|---|
| Up 5% | about 17 hours ago |
| Possible NR7 | about 18 hours ago |
| New 52 Week High | about 19 hours ago |
| Up 3% | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.0699 |
| 52 Week Low | 9.67 |
| Average Volume | 1,175,862 |
| 200-Day Moving Average | 13.64 |
| 50-Day Moving Average | 15.32 |
| 20-Day Moving Average | 15.00 |
| 10-Day Moving Average | 15.73 |
| Average True Range | 1.23 |
| RSI (14) | 61.24 |
| ADX | 21.3 |
| +DI | 34.40 |
| -DI | 15.70 |
| Chandelier Exit (Long, 3 ATRs) | 14.37 |
| Chandelier Exit (Short, 3 ATRs) | 16.72 |
| Upper Bollinger Bands | 17.32 |
| Lower Bollinger Band | 12.67 |
| Percent B (%b) | 1.08 |
| BandWidth | 30.99 |
| MACD Line | 0.39 |
| MACD Signal Line | 0.09 |
| MACD Histogram | 0.3019 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.80 | ||||
| Resistance 3 (R3) | 19.70 | 18.88 | 19.45 | ||
| Resistance 2 (R2) | 18.88 | 18.34 | 18.94 | 19.33 | |
| Resistance 1 (R1) | 18.29 | 18.01 | 18.58 | 18.39 | 19.22 |
| Pivot Point | 17.47 | 17.47 | 17.62 | 17.53 | 17.47 |
| Support 1 (S1) | 16.88 | 16.93 | 17.18 | 16.99 | 16.16 |
| Support 2 (S2) | 16.06 | 16.60 | 16.12 | 16.05 | |
| Support 3 (S3) | 15.47 | 16.06 | 15.93 | ||
| Support 4 (S4) | 15.58 |
